C3 Industries’ Brotherly Model for MSO Success

Founded in 2018, Michigan-based C3 Industries is a privately owned, vertically integrated cannabis company that has in short order expanded its retail, cultivation, and manufacturing operations from one state to…

News & Insights

Marijuana Testing for Recruits Could End Under House’s Must-Pass Defense Policy Bill

Potential military recruits and prospective officers soon may not need to worry about drug testing if they recently used marijuana. A provision included in the draft text of a must-pass…

CT Attorney General Announces ‘Settlement’ with HighBazaar

The headline of Tuesday’s announcement by Connecticut Attorney General William Tong stated that his office had reached a ‘settlement” with HighBazaar, the longstanding and very popular Connecticut sesh that earned…

BREAKING NEWS: DEA Issues Notice of Proposed Rulemaking to Move Marijuana to Schedule III

By Vince Śliwoski, Managing Partner of Harris Sliwoski Today is another historic day in the history of cannabis control and regulation. In a much anticipated announcement, the Drug Enforcement Administration…

New Hampshire Flirts With State-Run Franchises

Already a medical cannabis-legal state, New Hampshire is so unsure about legalizing cannabis for adult use that it appears willing to consider a quasi-regulatory structure that no other state has…

Schedule 3 Marijuana Alert: DEA Publishes NPRM

By Hilary Bricken, Attorney at Husch Blackwell On May 16, the Drug Enforcement Administration (“DEA“) published its 92-page notice of proposed rulemaking (“NPRM“) to move marijuana from schedule 1 on…

Ohio medical marijuana companies prepare to apply for dual-use license to sell recreational

Ohio medical marijuana companies are gearing up to begin the process of entering the recreational marijuana business. The Joint Committee on Agency Rule Review (JCARR) recently approved regulations from the Division of Cannabis…

Marijuana rescheduling moves businesses into ‘uncharted territory’

Marijuana business owners hoping to benefit from the Biden administration’s move to reschedule the drug may be in for disappointment, according to experts. The administration announced plans Thursday to move forward with…